News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
Subscribe To Our Newsletter & Stay Updated
